Universitätsklinikum Schleswig-Holstein (UKSH)

Perioperative Chemotherapy or Preoperative Chemoradiotherapy in Esophageal Cancer (2025) Hoeppner J, Brunner T, Schmoor C, Bronsert P, Kulemann B, Claus R, Utzolino S, et al. Journal article Multinational retrospective analysis of bridging therapy prior to chimeric antigen receptor t cells for relapsed/refractory acute lymphoblastic leukemia in children and young adults (2025) Breidenbach M, Bader P, Attarbaschi A, Rossig C, Meisel R, Metzler M, Subklewe M, et al. Journal article Discordance, accuracy and reproducibility study of pathologists' diagnosis of melanoma and melanocytic tumors (2025) Haggenmüller S, Wies C, Abels J, Winterstein JT, Heinlein L, Nogueira Garcia C, Utikal JS, et al. Journal article Heterozygous UBR5 variants result in a neurodevelopmental syndrome with developmental delay, autism, and intellectual disability (2025) Sabeh P, Dumas SA, Maios C, Daghar H, Korzeniowski M, Rousseau J, Lines M, et al. Journal article The prognostic relevance of pleural effusion in patients with COVID-19 - A German multicenter study (2025) Bucher AM, Dietz J, Ehrengut C, Müller L, Schramm D, Akinina A, Drechsel M, et al. Journal article Improved survival of advanced melanoma patients receiving immunotherapy with concomitant antithrombotic therapy - A multicenter study on 2419 patients from the prospective skin cancer registry ADOReg. (2025) Kött J, Zell T, Zimmermann N, Rünger A, Smit DJ, Abeck F, Geidel G, et al. Journal article Tumor budding and lymphovascular invasion as prognostic factors in p16-positive oropharyngeal squamous cell carcinomas. (2025) Stögbauer F, Wirth M, Lauterbach M, Wollenberg B, Schmidl B, Hoch CC, Ourailidis I, et al. Journal article A comparison of real-world data on adjuvant treatment in patients with stage III BRAF V600 mutated melanoma - Results of systematic literature research. (2025) Amaral T, Nanz L, Higuita LMS, Ascierto P, Berking C, Couselo EM, Donia M, et al. Journal article Idecabtagene vicleucel or ciltacabtagene autoleucel for relapsed or refractory multiple myeloma: An international multicenter study (2025) Merz M, Albici AM, von Tresckow B, Rathje K, Fenk R, Holderried T, Müller F, et al. Journal article Corrigendum to “Persistent immune-related adverse events after cessation of checkpoint inhibitor therapy: Prevalence and impact on patients' health-related quality of life” [Eur J Cancer 176 (2022) 88–99, (S0959804922005226), (10.1016/j.ejca.2022.08.029)] (2025) Schulz TU, Zierold S, Sachse MM, Pesch G, Tomsitz D, Schilbach K, Kähler KC, et al. Journal article, Erratum